Full Press Release Details
Gasser Professor of Medicine and Professor of Molecular Biology Pathology and Immunology Associate Director, for the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs Jeffery Henderson , MD, PhD Washington University Associate Professor of Medicine and Molecular Biology M ember, National Convalescent Plasma Project (CCPP19) Shmuel Shoham , MD Johns Hopkins University School of Medicine Associate Professor of Medicine M ember, National Convalescent Plasma Project (CCPP19) Susan Weis , PhD University of Pennsylvania Perelman School of Medicine Professor and Vice Chair, Department of Microbiology Co - Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens Oncology COVID - 19 Copyright 2021 Immunome, Inc.
DoD awarded, up to $13.3M in funding Select convalescent patients with strong anti - viral titer Antibody cocktail for potential prophylaxis and treatment Deep repertoire screening against multiple viral proteins Collect convalescent blood and isolate memory B cells Produce antibody mixture (up to 6 Abs) using recombinant manufacture Screen for anti - viral antibodies Discovery engine enables rapid isolation of antibodies against SARS - CoV - 2 and potentially other infectious agents Copyright 2021 Immunome, Inc.
Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Target Cluster 2 Target Cluster 5 Target Cluster 1 IMM20059 IMM20065 Target Cluster 3 IMM20091 IMM20130 Target Cluster 4 Target Cluster 6 13 22 22 2 10 2 A Highly Productive Platform; Outputs To Date: 300,000 hybridomas | 1,300 hits 50+ antibody / antigen pairs 3 Provides critical insights into cancer biology such as: Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment 1 - 2 Novel immune checkpoints that serve as functional, tumor - derived inhibitors of immunity Copyright 2021 Immunome, Inc.
Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not ye t b een approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these current or potential future product cand ida tes for the use for which such product candidates are being studied.
In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the releva nt subject. These statements are based on information available to us as of the date of this presentation. While we believe that information provides a reasonable basis for these statements, t hat information may be limited or incomplete.
These risks, uncertainties and other facto rs may cause our actual results to differ materially and adversely from what is contained in (or may be implied from) any forward - looking statements. We operate in a quickly evolving industry and it is not possible to predict all risks and uncertainties. Forward - looking stateme nts speak as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward - looking statements, whether as a result of new information, fu ture events or otherwise, except as may be required under applicable law.
Forward - looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions applicable to Immunome and our industry in gene ral that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with our ability to execute on our strategy, including with respect to the timing of our R&D efforts, regulatory filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any anti bod y therapeutics which may be developed by us; our ability to finance our operations; the impact of the COVID - 19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Se cur ities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in our filings and reports with the SEC.
Forward - looking statements include, but are not limited to, statements regardin g our financial position, strategy, business plans; expectations regarding the timing, progress and achievement of our research and development activities, preclinical studies, any clinical trials and regulatory filings and submissions; our abi li ty to secure and execute on partnerships and collaborations; our expectations regarding the activity and therapeutic potential of our current and future product candidates; our achievement of corporate milestones and the implementation of our business model; and the adequacy of our financial resources to support our operation s.
All statements other than those of historical fact in this presentation and accompanying oral commentary are forward - looking statements. Forward - loo king statements may be identified by terminology such as "believe," "anticipate," "plan," "may," "intend," "will," "should," "expect," "estimate," "potential" and "continue" and simi lar expressions, including the negative of these words, but not all forward - looking statements contain these words.